Glucagonlike peptide-1 receptor: An example of translational research in insulinomas: A review

Endocrinology and Metabolism Clinics of North America

Volumn 39, Issue 4, 2010, Pages 791-800

  Christ, Emanuel ^a   Wild, Damian ^b,c   Reubi, Jean Claude ^d  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

111In DOTA DPTA exendin 4; Glucagonlike peptide 1; Glucagonlike petide 1 receptor; Insulinoma

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; DOPA; EXENDIN 3; EXENDIN 4; FLUORINE 18; GALLIUM 68; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INDIUM 111; INSULIN; IODINE 125; PENTETIC ACID; UNCLASSIFIED DRUG;

CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG DISTRIBUTION; DRUG UPTAKE; ENDOCRINE SURGERY; ENDOCRINE TUMOR; GENE; GENE OVEREXPRESSION; GLP 1R GENE; GLUCOSE HOMEOSTASIS; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INSULINOMA; ISOTOPE LABELING; KNOCKOUT GENE; NEUROENDOCRINE TUMOR; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS TUMOR; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VOMITING;

ANIMALS; DIAGNOSTIC TECHNIQUES, ENDOCRINE; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULINOMA; MOLECULAR DIAGNOSTIC TECHNIQUES; MOLECULAR TARGETED THERAPY; PANCREATIC NEOPLASMS; RECEPTORS, GLUCAGON; TRANSLATIONAL RESEARCH;

EID: 78649353120     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2010.09.003     Document Type: Review

References (34)

1. Nauck M.A. Unraveling the science of incretin biology. Eur J Intern Med 2009, 20(Suppl 2):S303-S308.
2. Thorens B., Porret A., Buhler L., et al. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 1993, 42(11):1678-1682.
3. Gros L., Thorens B., Bataille D., et al. Glucagon-like peptide-1-(7-36) amide, oxyntomodulin, and glucagon interact with a common receptor in a somatostatin-secreting cell line. Endocrinology 1993, 133(2):631-638.
4. Wei Y., Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 1995, 358(3):219-224.
5. Nauck M.A., Vilsboll T., Gallwitz B., et al. Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care 2009, 32(Suppl 2):S223-S231.
6. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132(6):2131-2157.
7. Reubi J.C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003, 24(4):389-427.
8. Kwekkeboom D.J., de Herder W.W., Kam B.L., et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008, 26(13):2124-2130.
9. Reubi J.C., Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumors as molecular basis for in vivo multireceptor tumor targeting. Eur J Nucl Med 2003, 30(5):781-793.
10. Hansotia T., Drucker D.J. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice. Regul Pept 2005, 128(2):125-134.
11. Montrose-Rafizadeh C., Wang Y., Janczewski A.M., et al. Overexpression of glucagon-like peptide-1 receptor in an insulin-secreting cell line enhances glucose responsiveness. Mol Cell Endocrinol 1997, 130(1-2):109-117.
12. Korner M., Stockli M., Waser B., et al. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 2007, 48(5):736-743.
13. Plockinger U., Rindi G., Arnold R., et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. Neuroendocrinology 2004, 80(6):394-424.
14. Rostambeigi N., Thompson G.B. What should be done in an operating room when an insulinoma cannot be found?. Clin Endocrinol (Oxf) 2009, 70(4):512-515.
15. Chatziioannou A., Kehagias D., Mourikis D., et al. Imaging and localization of pancreatic insulinomas. Clin Imaging 2001, 25(4):275-283.
16. Kauhanen S., Seppanen M., Minn H., et al. Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or beta-cell hyperplasia in adult patients. J Clin Endocrinol Metab 2007, 92(4):1237-1244.
17. Tessonnier L., Sebag F., Ghander C., et al. Limited value of 18F-F-DOPA PET to localize pancreatic insulin-secreting tumors in adults with hyperinsulinemic hypoglycemia. J Clin Endocrinol Metab 2010, 95(1):303-307.
18. Wiesli P., Brandle M., Schmid C., et al. Selective arterial calcium stimulation and hepatic venous sampling in the evaluation of hyperinsulinemic hypoglycemia: potential and limitations. J Vasc Interv Radiol 2004, 15(11):1251-1256.
19. Reubi J.C., Maecke H.R. Peptide-based probes for cancer imaging. J Nucl Med 2008, 49(11):1735-1738.
20. Gotthardt M., Fischer M., Naeher I., et al. Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results. Eur J Nucl Med Mol Imaging 2002, 29(5):597-606.
21. Wild D., Behe M., Wicki A., et al. [Lys40(Ahx-DTPA-111In)NH2]Exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med 2006, 47(12):2025-2033.
22. Wicki A., Wild D., Storch D., et al. [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma. Clin Cancer Res 2007, 13(12):3696-3705.
23. Brom M, Oyen WJ, Joosten L, et al. (68)Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET. Eur J Nucl Med Mol Imaging 2010;37(7):1345-55.
24. Wild D, Wicki A, Mansi R, et al. Exendin-4-based radiopharmaceuticals for glucagon-like peptide-1 (GLP-1) receptor PET/CT and SPECT/CT imaging. J Nucl Med 2010;51(7):1059-67.
25. Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985, 315(6015):115-122.
26. Christ E., Wild D., Forrer F., et al. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metab 2009, 94(11):4398-4405.
27. McAuley G., Delaney H., Colville J., et al. Multimodality preoperative imaging of pancreatic insulinomas. Clin Radiol 2005, 60(10):1039-1050.
28. Wild D., Mäcke H., Christ E., et al. Glucagon-like peptide 1-receptor scans to localize occult insulinomas. N Engl J Med 2008, 359(7):766-768.
29. Wild D., Christ E., Forrer F., et al. 111In-DTPA-exendin-4 SPECT/CT scans localize hardly detectable insulinomas. J Nucl Med 2009, 50(Suppl 2):1937.
30. Christ E, Wild D, Caplin M, et al. Glucagon-like peptide-1 compared with somatostatin receptor2 targeting in malignant insulinoma [abstract]. Endocrine Soc Meeting 2010, in press.
31. Levine J.A., Burgart L.J., Batts K.P., et al. Brunner's gland hamartomas: clinical presentation and pathological features of 27 cases. Am J Gastroenterol 1995, 90(2):290-294.
32. Stolte M., Schwabe H., Prestele H. Relationship between diseases of the pancreas and hyperplasia of Brunner's glands. Virchows Arch A Pathol Anat Histol 1981, 394(1-2):75-87.
33. Yakovac W.C., Baker L., Hummeler K. Beta cell nesidioblastosis in idiopathic hypoglycemia of infancy. J Pediatr 1971, 79(2):226-231.
34. Service G.J., Thompson G.B., Service F.J., et al. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 2005, 353(3):249-254.